TrialBritish journal of cancer2023

A randomised phase 2 study of continuous or intermittent dosing schedule of imatinib re-challenge in patients with tyrosine kinase inhibitor-refractory gastrointestinal stromal tumours.

Hyung-Don Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.